LABT Stock Chart & Stats
$2.30
-$0.14(-5.30%)
At close: 4:00 PM EDT
$2.30
-$0.14(-5.30%)
Day’s Range― - ―
52-Week Range$1.66 - $98.20
Previous Close$2.46
Volume297.45K
Average Volume (3M)889.39K
Market Cap
$4.72M
Enterprise ValueN/A
Total Cash (Recent Filing)$4.58M
Total Debt (Recent Filing)$101.62K
Price to Earnings (P/E)―
Beta-2.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.02
Shares Outstanding2,369,688
10 Day Avg. Volume664,197
30 Day Avg. Volume889,389
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)-61.36
Price to Sales (P/S)0.00
P/FCF Ratio-61.99
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lakewood-Amedex Biotherapeutics Inc. News
LABT FAQ
What was Lakewood-Amedex Biotherapeutics Inc.’s price range in the past 12 months?
Lakewood-Amedex Biotherapeutics Inc. lowest stock price was $1.66 and its highest was $98.20 in the past 12 months.
What is Lakewood-Amedex Biotherapeutics Inc.’s market cap?
Lakewood-Amedex Biotherapeutics Inc.’s market cap is $4.72M.
When is Lakewood-Amedex Biotherapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lakewood-Amedex Biotherapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Lakewood-Amedex Biotherapeutics Inc. overvalued?
According to Wall Street analysts Lakewood-Amedex Biotherapeutics Inc.’s price is currently Overvalued.
Does Lakewood-Amedex Biotherapeutics Inc. pay dividends?
Lakewood-Amedex Biotherapeutics Inc. does not currently pay dividends.
What is Lakewood-Amedex Biotherapeutics Inc.’s EPS estimate?
Lakewood-Amedex Biotherapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lakewood-Amedex Biotherapeutics Inc. have?
Lakewood-Amedex Biotherapeutics Inc. has 2,369,688 shares outstanding.
What happened to Lakewood-Amedex Biotherapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lakewood-Amedex Biotherapeutics Inc.?
Currently, no hedge funds are holding shares in LABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Technical Analysis
AIM ImmunoTech
―
Kiora Pharmaceuticals
―
PharmaCyte Biotech
―
BioRestorative Therapies
―
Chemomab Therapeutics
―